Holen Sie sich die Stockscreener-App
0.1701
0.23%
-0.0004
Schlusskurs vom Vortag:
$0.1705
Offen:
$0.1659
24-Stunden-Volumen:
11.53M
Relative Volume:
0.86
Marktkapitalisierung:
$83.15M
Einnahmen:
$55.54M
Nettoeinkommen (Verlust:
$-180.40M
KGV:
-0.2159
EPS:
-0.7877
Netto-Cashflow:
$-170.32M
1W Leistung:
+0.24%
1M Leistung:
-4.97%
6M Leistung:
-93.25%
1J Leistung:
-90.05%
1-Tages-Spanne:
$0.1603
$0.1769
1-Wochen-Bereich:
$0.1138
$0.1769
52-Wochen-Spanne:
$0.1138
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1701 | 83.35M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Remains KeyPost-Announcement Reaction - dars.gov.et
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - AOL.com
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB - TradingView
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio (GOSS) Income Statement & Earnings - Moomoo
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - AOL.com
Gossamer Bio (GOSS) Q1 2025 earnings summary - Quartr
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes - Global Legal Chronicle
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - AOL.com
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - AOL.com
Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations - Ad-hoc-news.de
GOSSGossamer Bio Inc Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to earnings forward of Gossamer Bio, Inc. – DUS:4GB - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Connect - ACCESS Newswire
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes - Yahoo Finance
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
Form 13D/A Gossamer Bio For: 1 July By Investing.com - Investing.com Canada
GOSS: Gossamer Bio Sets Initial Conversion Rate for Convertible Notes - GuruFocus
Gossamer Bio sets conversion rate for 2030 convertible notes By Investing.com - Investing.com Nigeria
Gossamer Bio sets conversion rate for 2030 convertible notes - Investing.com
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants - marketscreener.com
Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan
Gossamer Bio fixes note conversion at $0.19, warrants at $0.34 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to revenue forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Enterprise value to EBITDA forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Price to book forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Price to sales forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Enterprise value to EBIT forward of Gossamer Bio, Inc. – SWB:4GB - TradingView
Price to sales forward of Gossamer Bio, Inc. – SWB:4GB - TradingView
Enterprise value to revenue forward of Gossamer Bio, Inc. – SWB:4GB - TradingView
Price to earnings forward of Gossamer Bio, Inc. – SWB:4GB - TradingView
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com - Investing.com Australia
GOSSAMER BIO INC (GOSS) Stock Chart - ChartMill
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange - Investing.com Nigeria
Gossamer Bio Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co. - Moomoo
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GOSS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Gossamer Bio, Inc. Actuals & Estimates (NASDAQ:GOSS) - TradingView
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):